

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 1E




Fig. 1F




Fig. 1G




Fig. 1H




Fig. 11




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 3A




Fig. 3B




Fig. 4A




Fig. 4B




Fig. 5




Fig. 6C




Fig. 6B




Fig. 6A




Fig. 6E





Fig. 6D



HT29

Fig. 7A




Fig. 7C




Fig. 7B





Fig. 7D



● 16D5 FcR1 TCB ● 9D11 FcR1 TCB ▲ DP47 TCB

Fig. 7E




Fig. 7F




Fig. 7G





Fig. 7H



● 16D5 FoIR1 TCB ● 9D11 FoIR1 TCB ▲ DP47 TCB

Fig. 7I




Fig. 7J




Fig. 7K







Fig. 7L



● 16D5 FcIR1 TCB ● 9D11 FcIR1 TCB ▲ DP47 TCB


Fig. 8





-●- Mov19 TCB -■- 9D11 TCB -▲- 16D5 TCB -▼- DP47 TCB

Fig. 10



SKOV3





Fig. 11B



- 9D11 FoLR1 TCB
- 9D11-T102N FoLR1 TCB
- 9D11-T102A FoLR1 TCB
- 9D11-N100S FoLR1 TCB
- 9D11-N100Q FoLR1 TCB

MKN45




Fig. 11D




Fig. 11F




Fig. 11E






Fig. 12A
HRPFig. 12B
HRC

—●— 16D5 FcIR1 TCB -■- 9D11 FcIR1 TCB -▲- DP47 TCB

Fig. 12C

HB





Fig. 12D

HT29



—●— 16D5 FoIR1 TCB -●- 9D11 FoIR1 TCB -▲- DP47 TCB

Fig. 12E





Fig. 12F



—●— 16D5 FoIR1 TCB -●- 9D11 FoIR1 TCB -▲- DP47 TCB

Fig. 12G









Fig. 12H



—●— 16D5 FoIR1 TCB -●- 9D11 FoIR1 TCB -▲- DP47 TCB



● 16D5 FcIR1 TCB ● 9D11 FcIR1 TCB ▲ DP47 TCB

Fig. 12M




Fig. 12N




Fig. 12O





Fig. 12P



—●— 16D5 FcR1 TCB -■- 9D11 FcR1 TCB -▲- DP47 TCB

Fig. 12Q




Fig. 12R




Fig. 12S






Fig. 12T



—●— 16D5 FcR1 TCB -●- 9D11 FcR1 TCB -▲- DP47 TCB

Fig. 12U



HT29

Fig. 12V




Fig. 12W





Fig. 12X



—●— 16D5 FcR1 TCB -●- 9D11 FcR1 TCB -▲- DP47 TCB

Fig. 13A




Fig. 13B




Fig. 13C




Fig. 14A




Fig. 14B






Fig. 14C



— 9D11 FoLR1 TCB 2+1 inverted — 9D11 FoLR1 TCB 1+1 classical ··· 9D11 FoLR1 TCB 1+1 head-to-tail

Fig. 15



Dose ug/mouse	Half-life Days
0.1	7.5
1	5.9
10	13.6

Fig. 16




Fig. 17A




Fig. 17B




Fig. 18




Fig. 19A






Fig. 19B








Fig. 21A





Fig. 21B



DP47 TCB kappa lambda FoIR1 TCB



Fig. 23A




Fig. 23B




Fig. 24B




Fig. 24A





Fig. 24C



% CD4⁺/CD25⁺ T cells, 48h

% CD8⁺/CD25⁺ T cells, 48h

% CD4⁺/CD69⁺ T cells, 48h

% CD8⁺/CD69⁺ T cells, 48h

antibody concentration (pM)

antibody concentration (pM)

antibody concentration (pM)

antibody concentration (pM)

36F2 TCB

16D5 TCB

DP47 TCB

Fig. 25B










Figure 1 consists of four graphs showing the effect of anti-CD25 antibody concentration on the percentage of CD4⁺ and CD8⁺ T cells at 48 hours. The graphs are arranged in a 2x2 grid. The x-axis for all graphs is 'antibody concentration (pM)' on a log scale from 0.01 to 10000. The y-axis is '% CD4⁺/CD25⁺ T cells, 48h' for the top row and '% CD8⁺/CD25⁺ T cells, 48h' for the bottom row. Three data series are shown: 36F2 TCB (filled squares), 16D5 TCB (open circles), and DP47 TCB (asterisks). In all cases, the percentage of T cells increases with antibody concentration, with 16D5 TCB showing the highest effect.

Antibody Concentration (pM)	% CD4 ⁺ /CD25 ⁺ T cells, 48h (36F2 TCB)	% CD4 ⁺ /CD25 ⁺ T cells, 48h (16D5 TCB)	% CD4 ⁺ /CD25 ⁺ T cells, 48h (DP47 TCB)	% CD8 ⁺ /CD25 ⁺ T cells, 48h (36F2 TCB)	% CD8 ⁺ /CD25 ⁺ T cells, 48h (16D5 TCB)	% CD8 ⁺ /CD25 ⁺ T cells, 48h (DP47 TCB)
0.01	~0	~0	~0	~0	~0	~0
1	~0	~10	~0	~0	~10	~0
10	~0	~30	~0	~0	~30	~0
100	~0	~45	~0	~0	~45	~0
1000	~0	~55	~0	~0	~55	~0
10000	~0	~60	~0	~0	~60	~0



■ 36F2 TCB
○ 16D5 TCB
× DP47 TCB

Fig. 27

Cell line	Binding sites	Cell line	Binding sites
Hela	2'240'716	Bronchial epithelium	492
Skov3	91'510	Choroid plexus epithelium	104
OVCAR5	22'077	Renal cortical epithelium	312
HT29	10'135	Retinal pigment epithelium	822
MKN45	54	Skov3	69'890




Fig. 28A




Fig. 28B

Fig. 29A




Fig. 29B




Fig. 30A




Fig. 30B




Fig. 31B





Fig. 31C

Fig. 31A




Fig. 32A







Fig. 32B















Fig. 33














Fig. 35B




Fig. 35D

Fig. 35A




Fig. 35C

Fig. 36A




Fig. 36B




Fig. 36C




Fig. 36D




Fig. 36E





Fig. 36F



16D5 TCB
36F2 TCB
6E10 TCB
14B1 TCB
9C7 TCB

Fig. 37A




Fig. 37B




Fig. 37C




Fig. 37D




Fig. 37E




Fig. 37F




Fig. 38A

HT-29




Fig. 38B

Retinal Pigment Epithelial Cells
(HRPEpic)




Fig. 38C

Renal Cortical Epithelial Cells
(HRCEpic)





Fig. 38D




Fig. 38E




Fig. 38F

Fig. 39A

Group	Construct	Mouse strain	Tumor	Dose (mg/kg)	Binder	Half live (days)	Cmax (ug/ml)
A	FOLR1 TCB (clone: 16D5 W96Y/D52E)	NOG	No	0.5	16D5 W96Y/D52E	10.6	16
B	FOLR1 TCB (clone: 16D5 G49S/S93A)	NOG	No	0.5	16D5 G49S/S93A	4.35	11
C	FOLR1 TCB (clone: 16D5)	NOG	No	0.5	16D5	13.6	10
D	FOLR1 TCB (clone: 36F2)	NOG	No	0.5	36F2	3.6	9




Fig. 39B

Fig. 40A

Group	Construct	PBMC injection (day 30)	Tumor (s.c.)	Start of treatment	Dose(mg/kg)	Scheduling
A	Vehicle	10x10 ⁶	HELA	Day 32	--	once per week
B	FOLR1 TCB (clone: 16D5)	10x10 ⁶	HELA	Day 32	0.5	once per week
C	FOLR1 TCB (clone: 16D5 W96Y/D52E)	10x10 ⁶	HELA	Day 32	2.5	once per week
D	FOLR1 TCB (clone: 16D5 W96Y/D52E)	10x10 ⁶	HELA	Day 32	0.5	once per week
E	FOLR1 TCB (clone: 16D5 G49S/S93A)	10x10 ⁶	HELA	Day 32	2.5	once per week
F	FOLR1 TCB (clone: 16D5 G49S/S93A)	10x10 ⁶	HELA	Day 32	0.5	once per week

Study protocol:




Fig. 40C




Fig. 40D





Fig. 40E






Fig. 40G




Fig. 40F




Fig. 41